A new test for diagnosing tuberculosis in all patients
Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen
This study is testing a new blood test called NanoPin that can quickly and accurately find active tuberculosis (TB) in people of all ages, including kids and those with HIV, to help doctors make better treatment decisions.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanopin Technologies, INC. NIH-funded |
| Lab location | 1 site (New Orleans, UNITED STATES) |
| Project ID | NIH-10671647 on NIH RePORTER |
What this research studies
This research focuses on developing a groundbreaking diagnostic tool called NanoPin, which aims to detect active tuberculosis (TB) quickly and accurately from blood samples. Unlike traditional methods that rely on sputum samples, this innovative approach can identify TB in various parts of the body, including the lungs, kidneys, and brain, making it suitable for all patient groups, including young children and those with HIV. The technology is designed to address critical gaps in TB diagnosis, particularly in regions with high rates of latent TB, by providing actionable results that can guide treatment decisions. By utilizing a highly sensitive platform, the research seeks to improve the speed and accuracy of TB detection, ultimately aiding in the global fight against this infectious disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of all ages, particularly young children and those co-infected with HIV, who are at higher risk for undiagnosed TB.
Not a fit: Patients who do not have tuberculosis or are not at risk for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnoses of tuberculosis, significantly improving patient outcomes and treatment initiation.
How similar studies have performed: Other research has shown promise in developing rapid diagnostic tests for tuberculosis, but the NanoPin approach is considered innovative and addresses specific unmet needs in the field.
Where this research is happening
New Orleans, UNITED STATES
- Nanopin Technologies, INC. — New Orleans, United States (Active)
Researchers
- Principal investigator: Tombler, Thomas W — Nanopin Technologies, INC.
- Study coordinator: Tombler, Thomas W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.